Tarlatamab has demonstrated superiority to lurbinectedin as a treatment for patients with ES-SCLC who have progressed after frontline chemoimmunotherapy.
Bingnan Zhang, MD, MBA
Advertisement
Articles by Bingnan Zhang, MD, MBA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
T-DXd Improves Invasive DFS vs T-DM1 in HER2+ Early Breast Cancer Subgroup
2
Certepetide/FOLFIRINOX Displays Encouraging Preliminary Feasibility in PDAC
3
FDA Advises Against BLA for Novel Vaccine Combo/Pembrolizumab in Melanoma
4
Introductions and an Overview of Multiple Myeloma Treatments
5
